CSL Behring GmbH (CSL Behring), formerly Aventis Behring GmbH, a subsidiary of CSL Ltd, offers a wide range of healthcare products which is derived from plasma protein biotherapeutics. The company provide products for coagulation disorders, immunoglobulins, chronic inflammatory demyelinating polyneuropathy, hereditary angioedema, haemophilia, alpha1-antitrypsin deficiency and immunodeficiencies. It offers patients different drugs based on plasma, a recombinant factor VIII and a fibrinolytic agent. CSL Behring conducts research in partnership with various academic institutions and organizations to develop plasma and recombinant products. CSL Behring GmbH is headquartered in Marburg, Germany.
Covid-19: Anti-inflammatory drugs do not lead to a swifter hospital exit
Study shows patients taking abatacept, cenicriviroc, or Remicade in addition to SOC do not recover quicker compared to placebo.
